NCT06412198 2026-03-06
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
Clinical Trials
10 trialsNCT05722327 2026-03-04
Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07318389 2026-02-27
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Not yet recruiting
NCT05578092 2026-02-19
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Mirati Therapeutics Inc.
Phase 1 Terminated
NCT06026410 2026-01-02
FIT-001
Kura Oncology, Inc.
Phase 1 Recruiting
NCT06764771 2025-12-17
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
Bristol-Myers Squibb
Phase 1 Active not recruiting
NCT03785249 2025-09-30
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics Inc.
Phase 1/2 Active not recruiting
NCT06039384 2025-08-03
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
Incyte Corporation
Phase 1 Terminated
NCT06024174 2025-07-22
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT04793958 2025-02-11
KRYSTAL-10
Mirati Therapeutics Inc.
Phase 3 Active not recruiting